Literature DB >> 16542258

Quantification of the prentice criteria for surrogate endpoints.

John O'Quigley1, Philippe Flandre.   

Abstract

In a recent discussion on the Prentice criteria for surrogate endpoints (1989) and the role of meta analyses in this context, Alonso et al. expand on a number of points. Among these is a suggestion to base a measure of the degree at which an endpoint meets the Prentice criteria on a likelihood reduction factor. Although new in this context, the suggestion has been studied elsewhere and the measure of Alonso et al., as presented, requires some modification if it is to be useful in general situations. As it stands it depends upon the censoring mechanism, even when independent of the failure mechanism. This is, however, easily fixed. The measure suggested by Alonso et al. can be seen to fit in with a well-established theory so that, once corrected for the presence of censoring, it can be employed with confidence. Of particular interest is the wide availability of a standard SAS program producing a coefficient which can be immediately transformed to provide an estimate of the population quantity behind the Alonso et al. proposal.

Mesh:

Substances:

Year:  2006        PMID: 16542258     DOI: 10.1111/j.1541-0420.2006.00538.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  An information-theoretic approach to surrogate-marker evaluation with failure time endpoints.

Authors:  Assam Pryseley; Abel Tilahun; Ariel Alonso; Geert Molenberghs
Journal:  Lifetime Data Anal       Date:  2010-09-28       Impact factor: 1.588

2.  Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria.

Authors:  G Heller
Journal:  Ann Oncol       Date:  2015-08-07       Impact factor: 32.976

3.  Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies.

Authors:  Bryan Lau; Stephen J Gange; Gregory D Kirk; Richard D Moore
Journal:  Epidemiology       Date:  2009-09       Impact factor: 4.822

4.  The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders.

Authors:  Bauke Schievink; Hiddo Lambers Heerspink; Hubert Leufkens; Dick De Zeeuw; Jarno Hoekman
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

5.  Potential Surrogate Outcomes for Kidney Failure in Advanced CKD: Evaluation of Power and Predictive Ability in CKDopps.

Authors:  Jarcy Zee; Daniel Muenz; Keith P McCullough; Brian Bieber; Marie Metzger; Natalia Alencar de Pinho; Antonio A Lopes; Danilo Fliser; Bruce M Robinson; Eric Young; Ronald L Pisoni; Bénédicte Stengel; Roberto Pecoits-Filho
Journal:  Kidney Med       Date:  2021-12-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.